Immunogen Stock Number Of Shares Shorted
| IMGNDelisted Stock | USD 31.23 0.01 0.03% |
ImmunoGen fundamentals help investors to digest information that contributes to ImmunoGen's financial success or failures. It also enables traders to predict the movement of ImmunoGen Stock. The fundamental analysis module provides a way to measure ImmunoGen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoGen stock.
ImmunoGen |
ImmunoGen Company Number Of Shares Shorted Analysis
ImmunoGen's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current ImmunoGen Number Of Shares Shorted | 20.61 M |
Most of ImmunoGen's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, ImmunoGen has 20.61 M of outstending shares currently sold short by investors. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The number of shares shorted for all United States stocks is significantly lower than that of the firm.
ImmunoGen Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoGen's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics of similar companies.ImmunoGen is currently under evaluation in number of shares shorted category among related companies.
ImmunoGen Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X | |||
| Price To Book | 15.53 X | |||
| Price To Sales | 30.33 X | |||
| Revenue | 287.61 M | |||
| Gross Profit | (104.76 M) | |||
| EBITDA | (78.46 M) | |||
| Net Income | (73.52 M) | |||
| Cash And Equivalents | 373.87 M | |||
| Cash Per Share | 1.69 X | |||
| Total Debt | 15.24 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.52 X | |||
| Book Value Per Share | 2.06 X | |||
| Cash Flow From Operations | (197.89 M) | |||
| Short Ratio | 3.78 X | |||
| Earnings Per Share | (0.28) X | |||
| Target Price | 31.06 | |||
| Number Of Employees | 277 | |||
| Beta | 1.17 | |||
| Market Capitalization | 8.72 B | |||
| Total Asset | 348.94 M | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 182.26 M | |||
| Current Asset | 253.11 M | |||
| Current Liabilities | 60.44 M | |||
| Net Asset | 348.94 M |
About ImmunoGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunoGen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunoGen's short interest history, or implied volatility extrapolated from ImmunoGen options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the ImmunoGen information on this page should be used as a complementary analysis to other ImmunoGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |